

Amendments to the Claims:

Please amend claims 1-2 and 17-18. Please cancel claim 19. Following entrance of this amendment, claims 1-2, 5-6 and 9-10 will be pending and under consideration.

The amendment to claims 1 and 2 find support throughout the specification, e.g., in the Examples wherein the results of human clinical trials are presented. The amendment to part b) of claim 18 fixes a typographical in which "during" has been replaced by "drug" (see, e.g., item 7 on page 6 of the specification).

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1. (Currently amended): A method of treating osteoarthritis in a ~~patient~~ human in need thereof comprising orally administering to said ~~patient~~ human a pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

Claim 2. (Currently amended): A method of inhibiting resorption and/or normalizing turnover of subchondral bone in a ~~patient~~ human having osteoarthritis or osteoporosis, or in a postmenopausal woman comprising orally administering to said ~~patient~~ human a pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof.

Claim 3-4. (Canceled)

Claim 5. (Previously Presented): The method according to claim 1, wherein the salmon calcitonin is conjugated to a polymer molecule.

Claim 6. (Previously Presented): The method according to claim 1, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.

Claim 7-8. (Canceled)

Claim 9. (Previously Presented): The method according to claim 6, whereas said pharmaceutical composition comprises a delivery agent selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 10. (Previously Presented): The method according to claim 9, whereas said pharmaceutical composition comprises a delivery agent in micronized form.

Claims 11-16. (Canceled)

Claim 17. (Withdrawn, Currently Amended): A pharmaceutical composition ~~for use in the treatment or/and prevention of osteoarthritis in a patient in need thereof,~~ comprising between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof ~~a calcitonin~~ together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim 18. (Withdrawn, Currently Amended): A pharmaceutical combination ~~for use in the treatment or/and prevention of osteoarthritis in a patient thereof,~~ comprising:

- a) ~~a first agent which is a calcitonin~~ between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof, and
- b) ~~a co-agent which is a bone resorption inhibitor, bone forming~~ drug ~~during or pain reducing agent.~~

Claim 19-23. (Canceled)